$COCP SEC Filings

Filed On	Filing
09 Sep 2026	8-K: Regulation FD Disclosure Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
21 Aug 2026	Form 3: Brosgart Carol L, Director No securities owned
18 Aug 2026	8-K: Departure/Election of Directors or Officers; Compensation
17 Aug 2026	8-K: Regulation FD Disclosure
13 Aug 2026	10-Q
07 Aug 2026	SCHEDULE 13D
07 Aug 2026	SCHEDULE 13D/A
06 Aug 2026	Form 4: Frost Phillip Md Et Al, Director Bought 10,000 shares ($9.82K)
05 Aug 2026	Form 4: Frost Phillip Md Et Al, Director Bought 75,000 shares ($70.6K)
03 Aug 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
17 Jul 2026	8-K: Submission of Matters to a Vote of Security Holders
09 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation
03 Jun 2026	Form 4: Sapirstein James, Chief Executive Officer Granted 235,000 Stock Options (Right to Buy)
03 Jun 2026	Form 3: Sapirstein James, Chief Executive Officer No securities owned
03 Jun 2026	8-K: Regulation FD Disclosure
27 May 2026	DEFA14A
27 May 2026	Proxy statement: annual meeting on July 14, 2026
26 May 2026	8-K: Regulation FD Disclosure
15 May 2026	10-Q
01 May 2026	EFFECT

Comments